The global market for Oral Drugs for Benign Prostatic Hyperplasia is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Oral Drugs for Benign Prostatic Hyperplasia market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Oral Drugs for Benign Prostatic Hyperplasia market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Oral Drugs for Benign Prostatic Hyperplasia market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Oral Drugs for Benign Prostatic Hyperplasia market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Oral Drugs for Benign Prostatic Hyperplasia players cover Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi and Pfizer, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Oral Drugs for Benign Prostatic Hyperplasia market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Oral Drugs for Benign Prostatic Hyperplasia market, with both quantitative and qualitative data, to help readers understand how the Oral Drugs for Benign Prostatic Hyperplasia market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Oral Drugs for Benign Prostatic Hyperplasia market and forecasts the market size by Type (Alpha Blockers, 5-alpha Reductase Inhibitors and Others), by Application (Hospitals, Drugstores and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Alpha Blockers
5-alpha Reductase Inhibitors
Others
Segmentation by application
Hospitals
Drugstores
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Viatris
Novartis
Merck
Chapter Introduction
Chapter 1: Scope of Oral Drugs for Benign Prostatic Hyperplasia, Research Methodology, etc.
Chapter 2: Executive Summary, global Oral Drugs for Benign Prostatic Hyperplasia market size (sales and revenue) and CAGR, Oral Drugs for Benign Prostatic Hyperplasia market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Oral Drugs for Benign Prostatic Hyperplasia sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Oral Drugs for Benign Prostatic Hyperplasia sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Oral Drugs for Benign Prostatic Hyperplasia market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Viatris, etc.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oral Drugs for Benign Prostatic Hyperplasia Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Oral Drugs for Benign Prostatic Hyperplasia by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Oral Drugs for Benign Prostatic Hyperplasia by Country/Region, 2017, 2022 & 2028
2.2 Oral Drugs for Benign Prostatic Hyperplasia Segment by Type
2.2.1 Alpha Blockers
2.2.2 5-alpha Reductase Inhibitors
2.2.3 Others
2.3 Oral Drugs for Benign Prostatic Hyperplasia Sales by Type
2.3.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2022)
2.3.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue and Market Share by Type (2017-2022)
2.3.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sale Price by Type (2017-2022)
2.4 Oral Drugs for Benign Prostatic Hyperplasia Segment by Application
2.4.1 Hospitals
2.4.2 Drugstores
2.4.3 Others
2.5 Oral Drugs for Benign Prostatic Hyperplasia Sales by Application
2.5.1 Global Oral Drugs for Benign Prostatic Hyperplasia Sale Market Share by Application (2017-2022)
2.5.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue and Market Share by Application (2017-2022)
2.5.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sale Price by Application (2017-2022)
3 Global Oral Drugs for Benign Prostatic Hyperplasia by Company
3.1 Global Oral Drugs for Benign Prostatic Hyperplasia Breakdown Data by Company
3.1.1 Global Oral Drugs for Benign Prostatic Hyperplasia Annual Sales by Company (2020-2022)
3.1.2 Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Company (2020-2022)
3.2 Global Oral Drugs for Benign Prostatic Hyperplasia Annual Revenue by Company (2020-2022)
3.2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Company (2020-2022)
3.2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Company (2020-2022)
3.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sale Price by Company
3.4 Key Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Product Location Distribution
3.4.2 Players Oral Drugs for Benign Prostatic Hyperplasia Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Oral Drugs for Benign Prostatic Hyperplasia by Geographic Region
4.1 World Historic Oral Drugs for Benign Prostatic Hyperplasia Market Size by Geographic Region (2017-2022)
4.1.1 Global Oral Drugs for Benign Prostatic Hyperplasia Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Oral Drugs for Benign Prostatic Hyperplasia Annual Revenue by Geographic Region
4.2 World Historic Oral Drugs for Benign Prostatic Hyperplasia Market Size by Country/Region (2017-2022)
4.2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Annual Sales by Country/Region (2017-2022)
4.2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Annual Revenue by Country/Region
4.3 Americas Oral Drugs for Benign Prostatic Hyperplasia Sales Growth
4.4 APAC Oral Drugs for Benign Prostatic Hyperplasia Sales Growth
4.5 Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Growth
4.6 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Growth
5 Americas
5.1 Americas Oral Drugs for Benign Prostatic Hyperplasia Sales by Country
5.1.1 Americas Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2017-2022)
5.1.2 Americas Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2022)
5.2 Americas Oral Drugs for Benign Prostatic Hyperplasia Sales by Type
5.3 Americas Oral Drugs for Benign Prostatic Hyperplasia Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Drugs for Benign Prostatic Hyperplasia Sales by Region
6.1.1 APAC Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2017-2022)
6.1.2 APAC Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2017-2022)
6.2 APAC Oral Drugs for Benign Prostatic Hyperplasia Sales by Type
6.3 APAC Oral Drugs for Benign Prostatic Hyperplasia Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oral Drugs for Benign Prostatic Hyperplasia by Country
7.1.1 Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2017-2022)
7.1.2 Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2022)
7.2 Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Type
7.3 Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia by Country
8.1.1 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2017-2022)
8.1.2 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2022)
8.2 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Type
8.3 Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Drugs for Benign Prostatic Hyperplasia
10.3 Manufacturing Process Analysis of Oral Drugs for Benign Prostatic Hyperplasia
10.4 Industry Chain Structure of Oral Drugs for Benign Prostatic Hyperplasia
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Drugs for Benign Prostatic Hyperplasia Distributors
11.3 Oral Drugs for Benign Prostatic Hyperplasia Customer
12 World Forecast Review for Oral Drugs for Benign Prostatic Hyperplasia by Geographic Region
12.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size Forecast by Region
12.1.1 Global Oral Drugs for Benign Prostatic Hyperplasia Forecast by Region (2023-2028)
12.1.2 Global Oral Drugs for Benign Prostatic Hyperplasia Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oral Drugs for Benign Prostatic Hyperplasia Forecast by Type
12.7 Global Oral Drugs for Benign Prostatic Hyperplasia Forecast by Application
13 Key Players Analysis
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.1.3 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.2.3 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Astellas Pharma
13.3.1 Astellas Pharma Company Information
13.3.2 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.3.3 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Astellas Pharma Main Business Overview
13.3.5 Astellas Pharma Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.4.3 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.5.3 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Abbott
13.6.1 Abbott Company Information
13.6.2 Abbott Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.6.3 Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Abbott Main Business Overview
13.6.5 Abbott Latest Developments
13.7 Allergan
13.7.1 Allergan Company Information
13.7.2 Allergan Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.7.3 Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Allergan Main Business Overview
13.7.5 Allergan Latest Developments
13.8 TEVA
13.8.1 TEVA Company Information
13.8.2 TEVA Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.8.3 TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 TEVA Main Business Overview
13.8.5 TEVA Latest Developments
13.9 Viatris
13.9.1 Viatris Company Information
13.9.2 Viatris Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.9.3 Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Viatris Main Business Overview
13.9.5 Viatris Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.10.3 Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Merck
13.11.1 Merck Company Information
13.11.2 Merck Oral Drugs for Benign Prostatic Hyperplasia Product Offered
13.11.3 Merck Oral Drugs for Benign Prostatic Hyperplasia Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Merck Main Business Overview
13.11.5 Merck Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Oral Drugs for Benign Prostatic Hyperplasia Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Oral Drugs for Benign Prostatic Hyperplasia Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Alpha Blockers
Table 4. Major Players of 5-alpha Reductase Inhibitors
Table 5. Major Players of Others
Table 6. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
Table 7. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2022)
Table 8. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Type (2017-2022) & ($ million)
Table 9. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Type (2017-2022)
Table 10. Global Oral Drugs for Benign Prostatic Hyperplasia Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
Table 12. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2022)
Table 13. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Application (2017-2022)
Table 14. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Application (2017-2022)
Table 15. Global Oral Drugs for Benign Prostatic Hyperplasia Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Company (2020-2022) & (K Units)
Table 17. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Company (2020-2022)
Table 18. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Company (2020-2022)
Table 20. Global Oral Drugs for Benign Prostatic Hyperplasia Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Producing Area Distribution and Sales Area
Table 22. Players Oral Drugs for Benign Prostatic Hyperplasia Products Offered
Table 23. Oral Drugs for Benign Prostatic Hyperplasia Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share Geographic Region (2017-2022)
Table 28. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country/Region (2017-2022)
Table 32. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2017-2022) & (K Units)
Table 35. Americas Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2017-2022)
Table 36. Americas Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2017-2022)
Table 38. Americas Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
Table 39. Americas Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2022)
Table 40. Americas Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
Table 41. Americas Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2022)
Table 42. APAC Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2017-2022) & (K Units)
Table 43. APAC Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2017-2022)
Table 44. APAC Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2017-2022)
Table 46. APAC Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
Table 47. APAC Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2022)
Table 48. APAC Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
Table 49. APAC Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2022)
Table 50. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2017-2022) & (K Units)
Table 51. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2017-2022)
Table 52. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2017-2022)
Table 54. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
Table 55. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2022)
Table 56. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
Table 57. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Oral Drugs for Benign Prostatic Hyperplasia
Table 67. Key Market Challenges & Risks of Oral Drugs for Benign Prostatic Hyperplasia
Table 68. Key Industry Trends of Oral Drugs for Benign Prostatic Hyperplasia
Table 69. Oral Drugs for Benign Prostatic Hyperplasia Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Oral Drugs for Benign Prostatic Hyperplasia Distributors List
Table 72. Oral Drugs for Benign Prostatic Hyperplasia Customer List
Table 73. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Forecast by Region
Table 75. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Oral Drugs for Benign Prostatic Hyperplasia Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Oral Drugs for Benign Prostatic Hyperplasia Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Oral Drugs for Benign Prostatic Hyperplasia Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Oral Drugs for Benign Prostatic Hyperplasia Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share Forecast by Application (2023-2028)
Table 93. Eli Lilly Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 94. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 95. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Eli Lilly Main Business
Table 97. Eli Lilly Latest Developments
Table 98. GlaxoSmithKline Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 99. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 100. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. GlaxoSmithKline Main Business
Table 102. GlaxoSmithKline Latest Developments
Table 103. Astellas Pharma Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 104. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 105. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. Astellas Pharma Main Business
Table 107. Astellas Pharma Latest Developments
Table 108. Sanofi Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 109. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 110. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Sanofi Main Business
Table 112. Sanofi Latest Developments
Table 113. Pfizer Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 114. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 115. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. Pfizer Main Business
Table 117. Pfizer Latest Developments
Table 118. Abbott Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 119. Abbott Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 120. Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 121. Abbott Main Business
Table 122. Abbott Latest Developments
Table 123. Allergan Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 124. Allergan Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 125. Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 126. Allergan Main Business
Table 127. Allergan Latest Developments
Table 128. TEVA Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 129. TEVA Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 130. TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 131. TEVA Main Business
Table 132. TEVA Latest Developments
Table 133. Viatris Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 134. Viatris Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 135. Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 136. Viatris Main Business
Table 137. Viatris Latest Developments
Table 138. Novartis Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 139. Novartis Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 140. Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 141. Novartis Main Business
Table 142. Novartis Latest Developments
Table 143. Merck Basic Information, Oral Drugs for Benign Prostatic Hyperplasia Manufacturing Base, Sales Area and Its Competitors
Table 144. Merck Oral Drugs for Benign Prostatic Hyperplasia Product Offered
Table 145. Merck Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 146. Merck Main Business
Table 147. Merck Latest Developments
List of Figures
Figure 1. Picture of Oral Drugs for Benign Prostatic Hyperplasia
Figure 2. Oral Drugs for Benign Prostatic Hyperplasia Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Alpha Blockers
Figure 10. Product Picture of 5-alpha Reductase Inhibitors
Figure 11. Product Picture of Others
Figure 12. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type in 2021
Figure 13. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Type (2017-2022)
Figure 14. Oral Drugs for Benign Prostatic Hyperplasia Consumed in Hospitals
Figure 15. Global Oral Drugs for Benign Prostatic Hyperplasia Market: Hospitals (2017-2022) & (K Units)
Figure 16. Oral Drugs for Benign Prostatic Hyperplasia Consumed in Drugstores
Figure 17. Global Oral Drugs for Benign Prostatic Hyperplasia Market: Drugstores (2017-2022) & (K Units)
Figure 18. Oral Drugs for Benign Prostatic Hyperplasia Consumed in Others
Figure 19. Global Oral Drugs for Benign Prostatic Hyperplasia Market: Others (2017-2022) & (K Units)
Figure 20. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2017-2022)
Figure 21. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Application in 2021
Figure 22. Oral Drugs for Benign Prostatic Hyperplasia Revenue Market by Company in 2021 ($ Million)
Figure 23. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Company in 2021
Figure 24. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Geographic Region (2017-2022)
Figure 25. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Geographic Region in 2021
Figure 26. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2017-2022)
Figure 27. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country/Region in 2021
Figure 28. Americas Oral Drugs for Benign Prostatic Hyperplasia Sales 2017-2022 (K Units)
Figure 29. Americas Oral Drugs for Benign Prostatic Hyperplasia Revenue 2017-2022 ($ Millions)
Figure 30. APAC Oral Drugs for Benign Prostatic Hyperplasia Sales 2017-2022 (K Units)
Figure 31. APAC Oral Drugs for Benign Prostatic Hyperplasia Revenue 2017-2022 ($ Millions)
Figure 32. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales 2017-2022 (K Units)
Figure 33. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue 2017-2022 ($ Millions)
Figure 34. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales 2017-2022 (K Units)
Figure 35. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue 2017-2022 ($ Millions)
Figure 36. Americas Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country in 2021
Figure 37. Americas Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country in 2021
Figure 38. United States Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 39. Canada Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 40. Mexico Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 41. Brazil Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 42. APAC Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region in 2021
Figure 43. APAC Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Regions in 2021
Figure 44. China Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 45. Japan Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 46. South Korea Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 47. Southeast Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 48. India Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 49. Australia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 50. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country in 2021
Figure 51. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country in 2021
Figure 52. Germany Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 53. France Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 54. UK Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 55. Italy Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 56. Russia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 57. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country in 2021
Figure 58. Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country in 2021
Figure 59. Egypt Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 60. South Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 61. Israel Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 62. Turkey Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 63. GCC Country Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth 2017-2022 ($ Millions)
Figure 64. Manufacturing Cost Structure Analysis of Oral Drugs for Benign Prostatic Hyperplasia in 2021
Figure 65. Manufacturing Process Analysis of Oral Drugs for Benign Prostatic Hyperplasia
Figure 66. Industry Chain Structure of Oral Drugs for Benign Prostatic Hyperplasia
Figure 67. Channels of Distribution
Figure 68. Distributors Profiles
Global Freckle-removing Medical and Beau..
The global market for Freckle-removing Medical and Beauty Eq..
+16467917070US (Toll Free)